US FDA approves Merck's RSV antibody for infants

The FDA has approved Merck's Enflonsia (clesrovimab), a preventive antibody shot for RSV in infants up to one year old, offering a new option amid supply constraints of Sanofi and AstraZeneca's Beyfortus. Enflonsia, a single-dose monoclonal antibody, protects against mild to severe RSV, a leading cause of infant hospitalization and death, with shipments expected for the 2025-2026 RSV season. The CDC's advisory committee will meet this month to discuss recommendations for Enflonsia's use.

Analysis

The U.S. Food and Drug Administration's approval of Merck’s (MRK) Enflonsia (clesrovimab) for respiratory syncytial virus (RSV) prevention in infants up to one year of age is a notable regulatory milestone, positioning Merck to enter a market currently experiencing supply limitations for the existing preventive option, Sanofi (SNY) and AstraZeneca's (AZN) Beyfortus. Enflonsia, a single-dose monoclonal antibody, aims to protect against mild, moderate, and severe RSV, a virus responsible for an estimated 58,000–80,000 hospitalizations annually in U.S. children under five. Merck's plan to have shipments ready for the 2025-2026 RSV season suggests a near-to-medium term revenue opportunity. A critical next step will be the upcoming CDC's Advisory Committee on Immunization Practices (ACIP) meeting, which will discuss and recommend Enflonsia's use, significantly influencing its adoption. The strongly positive sentiment signal for Merck (0.8) and the moderate market impact score (0.6) underscore the perceived commercial potential of this new product.

Key Decisions for Investors

• Investors should view the FDA approval of Enflonsia as a positive catalyst for Merck (MRK), with potential for a new revenue stream commencing in the 2025-2026 RSV season, particularly given the supply constraints of the competing product.
• Monitor the outcomes of the CDC's Advisory Committee on Immunization Practices meeting this month, as their recommendations will be pivotal for Enflonsia's market penetration and uptake in infants.
• Consider the potential for increased competition for Sanofi (SNY) and AstraZeneca (AZN) in the RSV prevention market following Enflonsia's entry, and assess any impact on their respective market shares.